Method of treating diabetic nephropathy by administering antibodies to vascular endothelial growth factor B (VEGF-B)
AssigneesCSL Limited, B-Creative Sweden AB
InventorsUlf Eriksson, Annelie Falkevall, Annika Mehlem
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of treating diabetic nephropathy in a subject suffering from diabetic nephropathy, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.
Claims11
A method of treating diabetic nephropathy in a subject suffering from type 1 diabetes and diabetic nephropathy, the method comprising administering to the subject an effective amount of a compound that inhibits VEGF-B signaling, wherein the compound is a nucleotide or is a protein comprising an antibody variable region that binds to or specifically binds to VEGF-B and neutralizes VEGF-B signaling.
A method of delaying the progression of diabetic nephropathy in a subject suffering from type 1 diabetes and microalbuminuria or macroalbuminuria, the method comprising administering to the subject an effective amount of a compound that inhibits VEGF-B signaling, wherein the compound is a nucleotide or is a protein comprising an antibody variable region that binds to or specifically binds to VEGF-B and neutralizes VEGF-B signaling.
Dependencies are inferred from the claim text.